• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cardiome Shares Takes a Hit Following FDA Denial

    Bryan Mc Govern
    Aug. 22, 2017 03:45PM PST
    Pharmaceutical Investing
    Pharmaceutical Investing

    Cardiome saw significant decreases on both its stocks as a reaction to the decision from the FDA.

    Cardiome Pharma (NASDAQ:CRME; TSX:COM) faced a decline in its stock Tuesday morning (August 22)–both on the NASDAQ and the TSX–after US Food and Drug Administration (FDA) regulators denied a New Drug Application (NDA) resubmission for Brinavess, a corrective treatment for an arrhythmic heartbeat.
    Dr. William Hunter, president and CEO of the company said the company requested a resubmission of the NDA taking a base of the six years Brinavess has been available in 33 countries.
    Despite the data Cardiome expected would back up their product, the agency replied saying that information would “not be sufficient.” Hunter added the company will continue their conversation with the FDA on the path for regulation.
    On the NASDAQ, Cardiome has suffered a 12.31 percent decline  in it stock following the denial of the FDA as of 3:55 p.m. EST, while on the TSX the decrease was 11.04 percent as of 3:40 p.m. EST on Tuesday.

    Cardiome “disappointed” with the FDA’s decision

    “We are disappointed that the Agency did not find these data compelling enough to recommend a resubmission, especially when several regulatory bodies in major jurisdictions around the world,” Hunter said.
    Cardiome said it still believes Brinavess is the best option available and will continue to explore every possible way for its entrance to the US market.
    Brinavess was approved by Health Canada, the country’s regulatory agency for medicine, earlier this year. A move which prompted Cardiome to expect an approval from the US. The drug will begin generating revenue for the company during their third quarter according to Jonathan Mather, director and global head of regulatory affairs with Cardiome.
    “We are pleased that Health Canada believed, as we do, that BRINAVESS provides an attractive alternative to the currently available treatment options of recent onset atrial fibrillation,” Mather said.
    Brinavess has also received approval in Europe, according to Cardiome, for “the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.”
    Cardiome released their financial report for the second quarter of the year on August 8 in which the company disclosed an $8.5 million net loss, turning to a $0.26 loss per share. Revenue saw a small decline to $5.8 million compared to the same period of time last year when Cardiome generated 5.9 million.
    According to reporting from BioPharma DIVE, Brinavess has been seeking US approval for over 10 years now and has fallen short on several roadblocks in its path to approval.

    Investor Takeaway

    Cardiome’s both US and Canadian stocks haven’t seen favourable performances. While an increase is visible during the summer months, the company’s recent news brought their stock back down. On a year-to-date period on the NASDAQ, shares of Cardiome have decreased 13.95 percent while on the TSX, the company’s stock is down 22.13 percent.
    Don’t forget to follow us @INN_LifeScience for real-time news updates
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    food and drug administrationpharmaceutical investingeuropecanadacardiome pharmafinancial report
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×